10/19/2009

The FDA wants more data on Novartis' proposed dosing for QAB149, a treatment for chronic obstructive pulmonary disease. The complete-response letter delays the approval of the drug, which was endorsed by the European Medicines Agency in September.

Full Story:
Reuters

Related Summaries